Posaconazole formulations not interchangeable

Tablet and oral suspension formulations of the antifungal posaconazole (Noxafil) are not interchangeable, warns the MHRA in its latest Drug Safety Update

Further information
View Noxafil drug record


Prescribers should specify the dosage form on each prescription to avoid confusion.

Switching from oral solution to tablets, or vice versa, can result in over- or under-dosing and the risk of dose-related toxicity or lack of efficacy.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

Cases of necrotising fasciitis of the genitalia or...

New advice for carbimazole over malformation and pancreatitis risks

New advice for carbimazole over malformation and pancreatitis risks

Reports of congenital malformations and acute pancreatitis...

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Antibiotic Treatments in Adults, Summary of Regimens

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.